The total pharmaceutical market in Norway displayed fluctuating trends between 2013 and 2023. The market saw a decline in values from 2013 through 2015, followed by an upward trend peaking in 2018. However, 2019 recorded a notable dip, with recovery observed from 2020 onward, achieving a value of 17.9 units in 2023. The year-on-year variations illustrate periods of inconsistencies aligned with economic and industry-specific influences. The compound annual growth rate (CAGR) over the last five years (2018-2023) averages a minor decline of -0.11%, indicating a relatively stable yet stagnant market.
Looking forward, the forecast suggests a continuing modest upward trajectory, with an anticipated CAGR of 0.66% from 2024 to 2028. By 2028, the market is projected to reach 18.6 units. This indicates a slow but steady growth rate of 3.33% over this period.
Future trends to watch for include potential impacts of regulatory changes, the introduction of innovative pharmaceutical products, and shifts in healthcare policies which could either bolster or impede market growth. Additionally, demographic changes and advancements in generic medicine adoption will be crucial factors influencing the market dynamics.
